CORRELATION BETWEEN CHEMOKINE RECEPTOR (CXCR4) EXPRESSION AND CLINICOPATHOLOGICAL FACTORS IN PATIENTS WITH PROSTATE CANCER

Lusan Abdulhameed Arkawazi a


a  Department of Pathology, College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.

Submitted: 30/2/2019; Accepted: 18/6/2019; Published: 21/6/2019


ABSTRACT


Background 

Prostate cancer is the second leading cause of cancer-related deaths. Different studies with conatroversial outcomes tried to find a link between CXCR4 level and other clinicopathological characters. 


Objectives 

To analyze the correlation of CXCR4 with prostate-specific antigen, age of the patients and Gleason score.


Materials and Methods

This is a retrospective cross-sectional study using paraffin-embedded blocks of prostate cancer. For CXCR4 visualization, immunohistochemistry (IHC) based on staining method for demonstration of its level was used to score them according to the extent and the staining intensity of the nucleus as: 0 (no signals for tissue staining), 1 (when tissue extent and intensity for staining is weak), 2 (extent and intensity of tissue staining is moderate), and 3 (when tissue extent and intensity staining is strong).


Results

Age of the patients ranged from 58-88 years, with the P value of 0.874 between the age and IHC staining score. The prostate-specific antigen level ranged from 9-100, the result was non-significant P value of 0.938 between PSA level and IHC staining score. There was also no significant relation between the level of CXCR4 (IHC staining score) and the Gleason score P value of 0.206.


Conclusion

High CXCR4 expression couldn’t be related to the clinical parameters such as pretreatment PSA level, the age of the patients, and histopathological findings of prostate cancer using Gleason score.


KEYWORDS

Prostate cancer, CXCR4, Prostate specific antigen, Immunohistochemistry, Plasma membrane, Transurethral resection of prostate.

References 
  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: a cancer journal for clinicians. 2009 Jul;59(4):225-49.
  2. Sneyd MJ. Ethnic differences in prostate cancer survival in New Zealand: a national study. Cancer Causes & Control. 2008 Nov 1;19(9):993-9.
  3.  Vindrieux D, Escobar P, Lazennec G. Emerging roles of chemokines in prostate cancer. Endocrine-related cancer. 2009 Sep 1;16(3):663.
  4.  Chen N, Zhou Q. The evolving Gleason grading system. Chinese Journal of Cancer Research. 2016 Feb;28(1):58..
  5. Bal MS, Kansal P, Singh H, Kaur N, Garg PK. Gleason's grading in Tru-Cut biopsy specimens of prostate carcinoma. Archives of International Surgery. 2013 May 1;3(2):132. 
  6. Jones KJ, Chetram MA, Bethea DA, Bryant LK, Odero-Marah V, Hinton CV. Cysteine (C)-XC receptor 4 regulates NADPH oxidase-2 during oxidative stress in prostate cancer cells. Cancer Microenvironment. 2013 Dec 1;6(3):277-88.
  7. Chetram MA, Don-Salu-Hewage AS, Hinton CV. ROS enhances CXCR4-mediated functions through inactivation of PTEN in prostate cancer cells. Biochemical and biophysical research communications. 2011 Jul 1;410(2):195-200.
  8. Don-Salu-Hewage AS, Chan SY, McAndrews KM, Chetram MA, Dawson MR, Bethea DA et al. Cysteine (C)-xC receptor 4 undergoes transportin 1-dependent nuclear localization and remains functional at the nucleus of metastatic prostate cancer cells. PloS one. 2013 Feb 28;8(2):e57194. 
  9. Chatterjee S, Azad BB, Nimmagadda S. The intricate role of CXCR4 in cancer. InAdvances in cancer research 2014 Jan 124:31-82.
  10. Choi WT, Duggineni S, Xu Y, Huang Z, An J. Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). Journal of medicinal chemistry. 2011 Dec 2;55(3):977-94.
  11. Squire JA. TMPRSS2-ERG and PTEN loss in prostate cancer. Nature genetics. 2009 May;41(5):509.
  12. Jung SJ, Kim CI, Park CH, Chang HS, Kim BH, Choi MS, et al. Correlation between chemokine receptor CXCR4 expression and prognostic factors in patients with prostate cancer. Korean journal of urology. 2011 Sep 1;52(9):607-11.
  13. Lu Z, Qi L, Bo XJ, Liu GD, Wang JM, Li G. Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2013 Aug;18(8):647.
  14. Okera M, Bae K, Bernstein E, Cheng L, Lawton C, Wolkov H, Pollack A, Dicker A, Sandler H, Sweeney CJ. Evaluation of nuclear factorκB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU international. 2011 Jul;108(2B):E51.
  15. Lee JY, Kang DH, Chung DY, Kwon JK, Lee H, Cho NH, et al. Meta-analysis of the relationship between CXCR4 expression and metastasis in prostate cancer. The world journal of men's health. 2014 Dec 1;32(3):167-75.
 


Creative Commons License © The Authors, published by University of Sulaimani, College of Medicine